Literature DB >> 11408235

Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

M L Cohn1, K B Waites.   

Abstract

We determined in vitro activities of gatifloxacin and seven other drugs against 100 isolates of Stenotrophomonas maltophilia using the agar gradient diffusion (Etest) method. Percentages of susceptible isolates were as follows: trimethoprim-sulfamethoxazole, 90%; gatifloxacin, 71%; levofloxacin, 57%; ticarcillin-clavulanic acid, 54%; ceftazidime, 49%; ciprofloxacin, 29%; cefepime, 21%; and piperacillin-tazobactam, 20%. Time-kill studies of three isolates indicated that gatifloxacin was bactericidal at times as early as 3 h of incubation when tested at concentrations equivalent to twice the MIC (two isolates) and 4 times the MIC (one isolate).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408235      PMCID: PMC90612          DOI: 10.1128/AAC.45.7.2126-2128.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Typing of 154 clinical isolates of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics.

Authors:  F J Schmitz; R Sadurski; J Verhoef; D Milatovic; A C Fluit
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.

Authors:  R Wise; J M Andrews; J P Ashby; J Marshall
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

3.  Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients.

Authors:  M E Villarino; L E Stevens; B Schable; G Mayers; J M Miller; J P Burke; W R Jarvis
Journal:  Infect Control Hosp Epidemiol       Date:  1992-04       Impact factor: 3.254

4.  Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.

Authors:  G Bonfiglio; C Cascone; C Azzarelli; V Cafiso; F Marchetti; S Stefani
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

5.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 7.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro.

Authors:  M Lecso-Bornet; J Pierre; D Sarkis-Karam; S Lubera; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

9.  Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.

Authors:  G A Pankuch; M R Jacobs; S F Rittenhouse; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Xanthomonas maltophilia bacteremia: an analysis of 32 cases.

Authors:  T N Jang; F D Wang; L S Wang; C Y Liu; I M Liu
Journal:  J Formos Med Assoc       Date:  1992-12       Impact factor: 3.282

  10 in total
  1 in total

Review 1.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.